Can-Fite BioPharma Ltd.
Stock Forecast, Prediction & Price Target
Can-Fite BioPharma Ltd. Financial Estimates
Can-Fite BioPharma Ltd. Revenue Estimates
Can-Fite BioPharma Ltd. EBITDA Estimates
Can-Fite BioPharma Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $853K N/A | $810K -5.04% | $743K -8.27% | Avg: $900K Low: $852.63K High: $947.36K avg. 21.13% | Avg: $800K Low: $757.89K High: $842.10K avg. -11.11% | Avg: $43.34M Low: $41.06M High: $45.63M avg. 5318.62% | Avg: $310.88K Low: $294.51K High: $327.24K avg. -99.28% |
Net Income
% change YoY
| $-12.59M N/A | $-10.23M 18.72% | $-7.63M 25.42% | Avg: $-4.72M Low: $-5.05M High: $-4.40M avg. 38.04% | Avg: $-213.05K Low: $-227.63K High: $-198.47K avg. 95.49% | Avg: $4.98M Low: $4.64M High: $5.32M avg. 2440.00% | Avg: $9.97M Low: $9.28M High: $10.65M avg. 100% |
EBITDA
% change YoY
| $-12.84M N/A | $-10.09M 21.38% | $-8.18M 18.97% | Avg: $-900K Low: $-947.36K High: $-852.63K avg. 88.99% | Avg: $-800K Low: $-842.10K High: $-757.89K avg. 11.11% | Avg: $-43.34M Low: $-45.63M High: $-41.06M avg. -5318.62% | Avg: $-310.88K Low: $-327.24K High: $-294.51K avg. 99.28% |
EPS
% change YoY
| -$6.83 N/A | -$3.76 44.94% | -$1.79 52.39% | Avg: -$1.11 Low: -$1.19 High: -$1.03 avg. 37.98% | Avg: -$0.05 Low: -$0.05 High: -$0.05 avg. 95.49% | Avg: $1.17 Low: $1.09 High: $1.25 avg. 2440% | Avg: $2.34 Low: $2.18 High: $2.5 avg. 100% |
Operating Expenses
% change YoY
| $13.69M N/A | $10.90M -20.36% | $8.93M -18.04% | Avg: $3.18M Low: $3.02M High: $3.35M avg. -64.31% | Avg: $2.83M Low: $2.68M High: $2.98M avg. -11.11% | Avg: $153.62M Low: $145.54M High: $161.71M avg. 5318.62% | Avg: $1.10M Low: $1.04M High: $1.15M avg. -99.28% |
FAQ
What is Can-Fite BioPharma Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 668.38% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -5.05M, average is -4.72M and high is -4.40M.
What is Can-Fite BioPharma Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1307.34% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $852.63K, average is $900K and high is $947.36K.
What is Can-Fite BioPharma Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 668.37% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$1.19, average is -$1.11 and high is $-1.03.